These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9041666)

  • 1. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.
    Miller E; Ashworth LA; Redhead K; Thornton C; Waight PA; Coleman T
    Vaccine; 1997 Jan; 15(1):51-60. PubMed ID: 9041666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
    Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
    Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
    Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
    Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
    Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
    Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules.
    Just M; Kanra G; Bogaerts H; Berger R; Ceyhan M; Pêtre J
    Dev Biol Stand; 1991; 73():275-83. PubMed ID: 1778319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine.
    Kosuwon P; Warachit B; Hutagalung Y; Borkird T; Kosalaraksa P; Bock HL; Poovorawan Y
    Vaccine; 2003 Oct; 21(27-30):4194-200. PubMed ID: 14505898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
    Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine.
    Vanura H; Just M; Ambrosch F; Berger RM; Bogaerts H; Wynen J; Vandevoorde D; Wiedermann G
    Vaccine; 1994; 12(3):210-4. PubMed ID: 8165852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team.
    Auerbach BS; Wilson ME; Lake AM; Deforest A; Steinhoff M; Halsey NA
    Vaccine; 1992; 10(1):14-20. PubMed ID: 1539456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
    Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
    Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.